Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Interviews

Interview
Advances in Deep Venous Arterialization and Coagulation Testing
01/19/2024
Vascular Disease Management spoke with Dr. Anahita Dua to discuss her VEITH presentations on these topics as well as the research she is doing at Massachusetts General Hospital on coagulation testing.
Vascular Disease Management spoke with Dr. Anahita Dua to discuss her VEITH presentations on these topics as well as the research she is doing at Massachusetts General Hospital on coagulation testing.
Vascular Disease Management...
01/19/2024
Vascular Disease Management
Interview
Current Studies of the MicroStent System for Treating PAD and CLI
01/17/2024
Vascular Disease Management spoke with Dr. Robert E. Beasley, who is the National Principal Investigator for the STAND Trial, to discuss the 2 current clinical studies in patients with chronic limb-threatening ischemia.
Vascular Disease Management spoke with Dr. Robert E. Beasley, who is the National Principal Investigator for the STAND Trial, to discuss the 2 current clinical studies in patients with chronic limb-threatening ischemia.
Vascular Disease Management...
01/17/2024
Vascular Disease Management
Interview
PROMISE II, PROMISE I, and European 2-Year Registry Results With Deep Vein Arterialization Using the LimFlow Device for CLTI With Gangrene
12/21/2023
VDM spoke with Dr. Clair to discuss the registry results and what they mean for patients with critical limb-threatening ischemia (CLTI).
VDM spoke with Dr. Clair to discuss the registry results and what they mean for patients with critical limb-threatening ischemia (CLTI).
VDM spoke with Dr. Clair to...
12/21/2023
Vascular Disease Management
Interview
VQI Collaboration With the International Consortium of Vascular Registries: How Can It Better Evaluate Aortic Endograft Performance? 
12/18/2023
We spoke with Dr. Adam Beck to discuss how these organizations are working together to improve EVAR.
We spoke with Dr. Adam Beck to discuss how these organizations are working together to improve EVAR.
We spoke with Dr. Adam Beck to...
12/18/2023
Vascular Disease Management
Interview
When Is the VenaSeal Closure System Appropriate for Patients With Ulcers and Combined Arterial and Venous Disease?
10/30/2023
Michael Shao, MD, RVPI, discusses his presentation at AMP 2023 about the VenaSeal closure system and when it is appropriate for use in combined arterial and venous disease.
Michael Shao, MD, RVPI, discusses his presentation at AMP 2023 about the VenaSeal closure system and when it is appropriate for use in combined arterial and venous disease.
Michael Shao, MD, RVPI,...
10/30/2023
Vascular Disease Management
Interview
Overcoming Barriers to Implementation of VOYAGER Results Into Everyday Practice
10/30/2023
Dr. Rogers provides insight into the barriers that may be preventing clinicians from implementing VOYAGER-PAD findings into everyday practice.
Dr. Rogers provides insight into the barriers that may be preventing clinicians from implementing VOYAGER-PAD findings into everyday practice.
Dr. Rogers provides insight into...
10/30/2023
Vascular Disease Management
Interview
Why Are We Failing to Prevent Amputations?
09/21/2023
At the 2023 Amputation Prevention Symposium (AMP), Mary Yost, MBA, president of the Sage Group, the leading research and consulting company specializing in peripheral vascular disease, presented her thoughts on the reasons why clinicians are...
At the 2023 Amputation Prevention Symposium (AMP), Mary Yost, MBA, president of the Sage Group, the leading research and consulting company specializing in peripheral vascular disease, presented her thoughts on the reasons why clinicians are...
At the 2023 Amputation...
09/21/2023
Vascular Disease Management
Interview
The TOBA II BTK Trial: A Sub-Analysis of the Long Lesion
09/21/2023
At the 2023 Amputation Prevention Symposium (AMP), cardiologist Lawrence Garcia, MD, presented a review of the findings from Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System in Below-the-Knee Arteries (TOBA II BTK)...
At the 2023 Amputation Prevention Symposium (AMP), cardiologist Lawrence Garcia, MD, presented a review of the findings from Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System in Below-the-Knee Arteries (TOBA II BTK)...
At the 2023 Amputation...
09/21/2023
Vascular Disease Management
Interview
Early Outcomes and Safety of Prostate Embolization With n-Butyl Cyanoacrylate Liquid Embolic
06/19/2023
Dr. Bamshad presented results from a retrospective study that assessed the feasibility, safety, and short-term efficacy of n-Butyl cyanoacrylate (n-BCA) glue embolization for prostate artery embolization.
Dr. Bamshad presented results from a retrospective study that assessed the feasibility, safety, and short-term efficacy of n-Butyl cyanoacrylate (n-BCA) glue embolization for prostate artery embolization.
Dr. Bamshad presented results...
06/19/2023
Vascular Disease Management
Interview
Risk Stratification and Mortality with Large Bore Thrombectomy for Intermediate and High-Risk Pulmonary Embolism
06/19/2023
At SIR 2023, Travis McKenzie, DO presented results from a retrospective cohort study that assessed risk and mortality with large bore thrombectomy for intermediate and high-risk PE.
At SIR 2023, Travis McKenzie, DO presented results from a retrospective cohort study that assessed risk and mortality with large bore thrombectomy for intermediate and high-risk PE.
At SIR 2023, Travis McKenzie, DO...
06/19/2023
Vascular Disease Management

Advertisement

Advertisement

Stay in the Know

Vascular Disease Management Newsletter

Advertisement

Advertisement

News

First Aid guidelines
AHA/American Red Cross: Updated First Aid Guidelines Enhance Care for Opioid Overdose, Bleeding, Other Emergencies
11/14/2024
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major comprehensive updates to the first aid guidelines since 2010 and address shifts in how the public manages common and critical first aid emergencies.
These are the first major...
11/14/2024
Cath Lab Digest
Late-Breaking Trials
Final Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/06/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the final round of Late-Breaking Clinical Trials presented at...
The VIVA Foundation, a...
11/06/2024
Vascular Disease Management
Late-Breaking Trials
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/05/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the third of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/05/2024
Vascular Disease Management
Late-Breaking Trials
Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Late-Breaking Trials
First Round of Late-Breaking Clinical Trial Results Announced at VIVA24
11/04/2024
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...
The VIVA Foundation, a...
11/04/2024
Vascular Disease Management
Image-Guided Therapy
Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease
11/04/2024
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...
With a unique world-first...
11/04/2024
Vascular Disease Management
Pulmonary Embolism
Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism
11/04/2024
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...
QUADRA-PE study will evaluate...
11/04/2024
Vascular Disease Management
Peripheral Arterial Disease
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
11/04/2024
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...
MOUNTAIN VIEW, Calif. – November...
11/04/2024
Vascular Disease Management
Patient Awareness
Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases
10/31/2024
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...
New survey reveals nearly one in...
10/31/2024
Vascular Disease Management
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement